Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alexion Pharmaceuticals, Inc.
The objective of this study is to characterize key aspects of the clinical course of LAL deficiency/Wolman phenotype in patients including, but not limited to, survival and growth parameters, to serve as a historical control to inform the evaluation and care of affected patients and to provide a reference for efficacy studies of enzyme replacement or other novel therapies.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Deceased patients diagnosed with LAL deficiency/Wolman phenotype in 1985 or later provided they have required data points in their medical records.
You may not be if
Patients will be excluded from the study if the required data points for inclusion are not available.
Living LAL deficiency/Wolman phenotype patients will be excluded